Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score-Matched cohort study.
People taking tirzepatide had fewer recorded dental problems than those on GLP-1 drugs, though confirmation in prospective studies is needed.
A very large matched electronic-health-record cohort associated tirzepatide with fewer recorded oral and periodontal events than GLP-1 receptor agonists. Residual confounding and low event rates mean that prospective confirmation is required.
What the study was
- Study design
- Global retrospective propensity score-matched cohort study
- Population
- Adults with type 2 diabetes treated with tirzepatide or GLP-1 receptor agonists
- Sample size
- 195986
- Category
- Public Health
- Maturity
- Validated
- Journal
- Diabetes research and clinical practice
Why it surfaced
The exceptionally large comparative cohort has near-term clinical relevance, but its observational design precludes causal claims.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.